Ring Therapeutics was founded by Flagship Pioneering in 2017 with the goal of developing a commensal virome platform for use in gene therapies. The company has developed an anellovirus database with thousands of newly discovered anello-based vector candidates.

Ring has also built a platform to harness the unique properties of commensal anelloviruses to generate an array of vectors with tissue-specific tropism and the ability to potentially be redosed. The anellovirus vectors carry circular, single-stranded DNA molecules that do not integrate with human DNA, thereby overcoming a key limitation of current viral gene therapy approaches. Ring's vector platform is fully integrated for the discovery and vectorization of anelloviruses to produce programmable medicines.

The series B financing round included contributions by Invus, Altitude Life Science Ventures, Partners Investment, and UPMC Enterprises, as well as funds and accounts advised by T. Rowe Price Associates.